Syros Pharmaceuticals, Inc.
SYRS
$0.032
-$0.0067-17.31%
OTC PK
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -6.50% | -10.96% | |||
| Gross Profit | 6.50% | 10.96% | |||
| SG&A Expenses | 3.51% | -12.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.50% | -11.34% | |||
| Operating Income | 4.50% | 11.34% | |||
| Income Before Tax | 72.58% | -529.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 72.58% | -529.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 72.58% | -529.10% | |||
| EBIT | 4.50% | 11.34% | |||
| EBITDA | 4.53% | 11.45% | |||
| EPS Basic | 72.63% | -524.61% | |||
| Normalized Basic EPS | 72.64% | -524.03% | |||
| EPS Diluted | 72.63% | -524.61% | |||
| Normalized Diluted EPS | 72.64% | -524.03% | |||
| Average Basic Shares Outstanding | 0.17% | 0.75% | |||
| Average Diluted Shares Outstanding | 0.17% | 0.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||